PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases

FORT WORTH, Texas & MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, and RareSight, Inc., an ophthalmology-focused life sciences company committed to advancing therapies for inherited retinal diseases (IRDs), today announced a strategic collaboration to develop first-in-class therapies for rare pediatric retinal diseases that curr